Medical Device | January 25, 2022
Agilent announces the Innovative Seahorse XF Pro Analyzer
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Subscribe To Our Newsletter & Stay Updated
